FierceBiotech Mar 19, 2026 Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals
FierceBiotech Mar 19, 2026 Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
Endpoints News Mar 19, 2026 Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
BioPharma Dive Mar 12, 2026 Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
Endpoints News Mar 12, 2026 Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News Mar 11, 2026 Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Pharmaron Mar 11, 2026 Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Endpoints News Mar 6, 2026 Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News Feb 24, 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
BioPharma Dive Feb 23, 2026 Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Endpoints News Feb 23, 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial